Drug
Ly4175408
Ly4175408: highest development phase Phase 1, developed by Eli Lilly. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Eli Lilly
Trials
| Drug | Phase | Indication |
|---|---|---|
| LY4175408 NCT07046923 | Phase 1 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Ly4175408 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.